• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Pooled analyses of sugammadex efficacy in surgical patients: no clinically relevant effect of subject characteristics

Pooled analyses of sugammadex efficacy in surgical patients: no clinically relevant effect of subject characteristics

W. Joseph Herring, MD, PhD1, Tiffany Woo, MS1, Christopher Assaid, PhD1, Terri Monk, MD2, Scott Groudine, MD3. 1Merck & Co., Inc., 2University of Missouri, 3Albany Medical Center

Objective of the technology: Sugammadex, a modified gamma cyclodextrin, is a novel reversal agent with the unique ability to encapsulate the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium, preventing their binding to nicotinic receptors at the neuromuscular junction, thereby reversing neuromuscular blockade (NMB). This innovative mechanism of action distinguishes sugammadex from other reversal agents based on the inhibition of acetylcholine esterase which has no effect on cholinergic neurotransmitters/ receptors which allows for reliable and rapid reversal of both NMB, providing flexibility for use in laparoscopic procedures.  Analysis of pooled efficacy data from the global sugammadex clinical database (N=1187) was performed to evaluate potential effects of the subject characteristics of age, body mass index (BMI), sex, ASA class, race and ethnicity. Results of the pooled analyses showed similar geometric mean recovery times within each subpopulation category for both sugammadex 2 and 4 mg/kg. Adverse event incidence was also similar within the subpopulations. No dose adjustment is therefore necessary based on these subject characteristics.

Description of the Technology and Method of Use:  Sugammadex represents a fundamentally different approach to the reversal of NMB, compared with currently available options.  The selective relaxant-binding agent sugammadex provides rapid reversal of rocuronium- and vecuronium-induced NMB when administered at 2 mg/kg for reversal of moderate (reappearance of T2 of the train-of-four [TOF]) NMB, and 4 mg/kg for deep (1-2 post-tetanic counts [PTC]) NMB. Analyses of key subject characteristics were performed across pooled data from the global sugammadex clinical database to evaluate potential impact on sugammadex efficacy, safety, or dosing requirements.ata were pooled across Phase I-III placebo-controlled studies from the sugammadex clinical database for healthy adult subjects and surgical patients who received sugammadex 2 mg/kg (for reversal of moderate NMB [reappearance of T2]) or 4 mg/kg (deep NMB [1-2 PTC]) together with anesthesia for reversal of rocuronium- or vecuronium-induced NMB. Geometric mean (95% CI) time from study drug administration until recovery of the TOF ratio to 0.9 was evaluated by the subpopulations of age, sex, BMI, ASA class, race and ethnicity, for the pooled dataset by dose group. Evaluation of adverse event (AE) incidence was also conducted across these subpopulations.

Results: In total, 1187 patients were included who received sugammadex following rocuronium/vecuronium. Pooled data showed sugammadex-mediated overall recovery to be rapid: for reversal of moderate NMB (sugammadex 2 mg/kg), geometric mean (95% CI) recovery was 1.9 (1.8, 2.0) min and 2.9 (2.5, 3.4) min for rocuronium and vecuronium respectively; and for reversal of deep NMB (4 mg/kg) was 2.2 (2.1– 2.3) min and 3.8 (3.0– 5.0) min, respectively. Geometric mean (95% CI) times to recovery were similar within each subpopulation category (Table). AE incidence was similar within the subpopulations, with no clinically relevant differences between the treatment groups/doses.

Conclusions: Analysis of pooled data across the sugammadex database found no clinically relevant effect of age, sex, BMI, ASA class, race or ethnicity on efficacy of sugammadex 2 or 4 mg/kg. Sugammadex was generally well-tolerated in these demographic categories. Therefore, no dose adjustment is necessary based on these subject characteristics.

243

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals